Patient characteristics
| Characteristic . | Whole cohort . | TCD . | PTCy . | CNI . | CNI+ATG . | P value . |
|---|---|---|---|---|---|---|
| No. of patients | 2089 | 207 | 304 | 1203 | 375 | |
| No. of centers | 105 | 30 | 46 | 94 | 63 | |
| Patient related | ||||||
| Recipient age, n (%) | <.01∗ | |||||
| Median age (range), y | 51 (2-75) | 52 (3-74) | 56 (2-74) | 47 (2-75) | 53 (2-74) | |
| <.01∗ | ||||||
| <20 years | 459 (22.0) | 43 (20.8) | 23 (7.6) | 307 (25.5) | 86 (22.9) | |
| ≥20 years | 1630 (78.0) | 164 (79.2) | 281 (92.4) | 896 (74.5) | 289 (77.1) | |
| Recipient sex, n (%) | .55∗ | |||||
| Male | 1190 (57) | 126 (61) | 177 (58) | 672 (56) | 215 (57) | |
| Female | 899 (43) | 81 (39) | 127 (42) | 531 (44) | 160 (43) | |
| Recipient race, n (%) | .01∗ | |||||
| White | 1650 (79) | 157 (76) | 221 (73) | 965 (80) | 307 (82) | |
| African American | 235 (11) | 33 (16) | 52 (17) | 109 (9) | 41 (11) | |
| Asian | 100 (5) | 10 (5) | 15 (5) | 60 (5) | 15 (4) | |
| Native Hawaiian or other Pacific Islander | 9 (0) | 1 (0) | 1 (0) | 7 (1) | 0 (0) | |
| American Indian or Alaska Native | 9 (0) | 0 (0) | 0 (0) | 6 (0) | 3 (1) | |
| ≥1 race | 22 (1) | 0 (0) | 4 (1) | 14 (1) | 4 (1) | |
| Missing | 64 (3) | 6 (3) | 11 (4) | 42 (3) | 5 (1) | |
| Ethnicity, n (%) | .02∗ | |||||
| Hispanic or Latino | 223 (11) | 16 (8) | 33 (11) | 146 (12) | 28 (7) | |
| Not Hispanic or Latino | 1816 (87) | 189 (91) | 267 (88) | 1020 (85) | 340 (91) | |
| Nonresident of the United States | 9 (0) | 2 (1) | 1 (0) | 6 (0) | 0 (0) | |
| Missing | 41 (2) | 0 (0) | 3 (1) | 31 (3) | 7 (2) | |
| HCT-CI score, n (%) | <.01∗ | |||||
| 0 | 582 (28) | 50 (24) | 54 (18) | 358 (30) | 120 (32) | |
| 1 | 298 (14) | 27 (13) | 45 (15) | 175 (15) | 51 (14) | |
| 2 | 295 (14) | 30 (14) | 46 (15) | 170 (14) | 49 (13) | |
| ≥3 | 912 (44) | 100 (48) | 159 (52) | 498 (41) | 155 (41) | |
| Missing | 2 (0) | 0 (0) | 0 (0) | 2 (0) | 0 (0) | |
| Previous autologous transplant, n (%) | .17∗ | |||||
| No | 2045 (98) | 199 (96) | 301 (99) | 1178 (98) | 367 (98) | |
| Yes | 44 (2) | 8 (4) | 3 (1) | 25 (2) | 8 (2) | |
| Karnofsky/Lansky performance score, n (%) | .02∗ | |||||
| <90 | 729 (35) | 67 (32) | 125 (41) | 402 (33) | 135 (36) | |
| ≥90 | 1348 (65) | 139 (67) | 175 (58) | 798 (66) | 236 (63) | |
| Missing | 12 (1) | 1 (0) | 4 (1) | 3 (0) | 4 (1) | |
| ALC at HCT, median (range), ×109/L | 2.3 (0.0-77.3) | 2.0 (0.0-77.3) | 2.4 (0.0-23.0) | 2.3 (0.0-74.5) | 2.2 (0.0-42.4) | .50† |
| Missing | 101 (5) | 6 (3) | 7 (2) | 67 (6) | 21 (6) | .05∗ |
| Donor related | ||||||
| Donor age, y | <.01∗ | |||||
| Median (range) | 36 (18-76) | 40 (19-73) | 36 (18-74) | 36 (18-76) | 31 (18-70) | |
| Donor sex, n (%) | .01∗ | |||||
| Male | 1238 (59) | 117 (57) | 199 (65) | 686 (57) | 236 (63) | |
| Female | 805 (39) | 87 (42) | 104 (34) | 483 (40) | 131 (35) | |
| Missing | 46 (2) | 3 (1) | 1 (0) | 34 (3) | 8 (2) | |
| Donor/recipient CMV serostatus, n (%) | <.01∗ | |||||
| +/+ | 511 (24) | 62 (30) | 121 (40) | 236 (20) | 92 (25) | |
| +/− | 173 (8) | 16 (8) | 32 (11) | 83 (7) | 42 (11) | |
| −/+ | 424 (20) | 34 (16) | 82 (27) | 226 (19) | 82 (22) | |
| −/− | 424 (20) | 51 (25) | 67 (22) | 207 (17) | 99 (26) | |
| CB −/recipient + | 333 (16) | 30 (14) | 0 (0) | 267 (22) | 36 (10) | |
| CB −/recipient − | 198 (9) | 11 (5) | 0 (0) | 167 (14) | 20 (5) | |
| CB −/recipient CMV unknown | 7 (0) | 0 (0) | 0 (0) | 7 (1) | 0 (0) | |
| Missing | 19 (1) | 3 (1) | 2 (1) | 10 (1) | 4 (1) | |
| Disease related | ||||||
| Disease, n (%) | <.01∗ | |||||
| AML | 974 (47) | 101 (49) | 157 (52) | 562 (47) | 154 (41) | |
| ALL | 460 (22) | 43 (21) | 64 (21) | 296 (25) | 57 (15) | |
| MDS | 655 (31) | 63 (30) | 83 (27) | 345 (29) | 164 (44) | |
| Time from diagnosis to transplant, median (range), d | 7 (1-549) | 7 (1-370) | 7 (2-549) | 7 (1-364) | 8 (1-497) | .01† |
| AML/ALL disease status, n (%) | .10∗ | |||||
| CR1 | 887 (62) | 92 (64) | 140 (63) | 523 (61) | 132 (63) | |
| CR2 | 348 (24) | 31 (22) | 48 (22) | 219 (26) | 50 (24) | |
| CR≥3 | 56 (4) | 4 (3) | 4 (2) | 40 (5) | 8 (4) | |
| PIF/relapse | 142 (10) | 16 (11) | 29 (13) | 76 (9) | 21 (10) | |
| Missing | 1 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | |
| AML/ALL cytogenetic score, n (%) | .09∗ | |||||
| Normal | 89 (6) | 8 (6) | 9 (4) | 65 (8) | 7 (3) | |
| Favorable | 102 (7) | 9 (6) | 11 (5) | 61 (7) | 21 (10) | |
| Intermediate | 613 (43) | 65 (45) | 100 (45) | 348 (41) | 100 (47) | |
| Poor | 597 (42) | 56 (39) | 99 (45) | 364 (42) | 78 (37) | |
| Not tested | 10 (1) | 3 (2) | 0 (0) | 5 (1) | 2 (1) | |
| Missing | 23 (1) | 3 (2) | 2 (1) | 15 (2) | 3 (1) | |
| MDS IPSS-R cytogenetic score, n (%) | <.01∗ | |||||
| Very good | 6 (1) | 0 (0) | 0 (0) | 4 (1) | 2 (1) | |
| Good | 287 (44) | 23 (37) | 38 (46) | 154 (45) | 72 (44) | |
| Intermediate | 157 (24) | 15 (24) | 18 (22) | 78 (23) | 46 (28) | |
| Poor | 99 (15) | 6 (10) | 9 (11) | 57 (17) | 27 (16) | |
| Very poor | 90 (14) | 12 (19) | 17 (20) | 46 (13) | 15 (9) | |
| Not tested | 8 (1) | 4 (6) | 1 (1) | 2 (1) | 1 (1) | |
| Missing | 8 (1) | 3 (5) | 0 (0) | 4 (1) | 1 (1) | |
| Conditioning intensity, n (%) | <.01∗ | |||||
| MAC | 1370 (66) | 165 (80) | 133 (44) | 846 (70) | 226 (60) | |
| RIC | 480 (23) | 35 (17) | 49 (16) | 271 (23) | 125 (33) | |
| NMA | 237 (11) | 6 (3) | 121 (40) | 86 (7) | 24 (6) | |
| Missing | 2 (0) | 1 (0) | 1 (0) | 0 (0) | 0 (0) | |
| Graft type, n (%) | <.01∗ | |||||
| BM | 336 (16) | 3 (1) | 95 (31) | 178 (15) | 60 (16) | |
| PB | 1215 (58) | 163 (79) | 209 (69) | 584 (49) | 259 (69) | |
| CB | 538 (26) | 41 (20) | 0 (0) | 441 (37) | 56 (15) | |
| Donor group, n (%) | <.01∗ | |||||
| HLA-identical sibling | 412 (20) | 28 (14) | 20 (7) | 322 (27) | 42 (11) | |
| Other related: matched | 27 (1) | 3 (1) | 7 (2) | 17 (1) | 0 (0) | |
| Other related: mismatched 1 antigen/allele | 20 (1) | 2 (1) | 11 (4) | 4 (0) | 3 (1) | |
| Other related: mismatched ≥2 antigen/allele | 269 (13) | 63 (30) | 196 (64) | 9 (1) | 1 (0) | |
| Other related: matching missing | 22 (1) | 3 (1) | 15 (5) | 3 (0) | 1 (0) | |
| Well matched unrelated (8/8) | 670 (32) | 49 (24) | 40 (13) | 369 (31) | 212 (57) | |
| Partially matched unrelated (7/8) | 107 (5) | 15 (7) | 11 (4) | 30 (2) | 51 (14) | |
| Mismatched unrelated (≤6/8) | 11 (1) | 2 (1) | 3 (1) | 1 (0) | 5 (1) | |
| Unrelated (matching unknown) | 13 (1) | 1 (0) | 1 (0) | 7 (1) | 4 (1) | |
| Single cord | 224 (11) | 36 (17) | 0 (0) | 148 (12) | 40 (11) | |
| Double cord | 313 (15) | 5 (2) | 0 (0) | 292 (24) | 16 (4) | |
| CB, single or double unknown | 1 (0) | 0 (0) | 0 (0) | 1 (0) | 0 (0) | |
| GVHD prophylaxis, n (%) | <.01∗ | |||||
| Ex vivo TCD | 62 (3) | 62 (30) | 0 (0) | 0 (0) | 0 (0) | |
| CD34 selection | 145 (7) | 145 (70) | 0 (0) | 0 (0) | 0 (0) | |
| PTCy + other(s) | 286 (14) | 0 (0) | 286 (94) | 0 (0) | 0 (0) | |
| PTCy alone | 18 (1) | 0 (0) | 18 (6) | 0 (0) | 0 (0) | |
| TAC/CSA + MMF ± other(s) (except PTCy) | 662 (32) | 0 (0) | 0 (0) | 537 (45) | 125 (33) | |
| TAC/CSA + MTX ± other(s) (except MMF, PTCy) | 788 (38) | 0 (0) | 0 (0) | 573 (48) | 215 (57) | |
| TAC/CSA + other(s) (except MMF, MTX, and PTCy) | 128 (6) | 0 (0) | 0 (0) | 93 (8) | 35 (9) | |
| ATG/Campath, n (%) | <.01∗ | |||||
| ATG alone | 501 (24) | 126 (61) | 0 (0) | 0 (0) | 375 (100) | |
| No ATG or alemtuzumab | 1588 (76) | 81 (39) | 304 (100) | 1203 (100) | 0 (0) | |
| Steroids, days 0-100, n (%) | <.01∗ | |||||
| No | 1202 (58) | 152 (73) | 200 (66) | 620 (52) | 230 (61) | |
| Yes | 887 (42) | 55 (27) | 104 (34) | 583 (48) | 145 (39) | |
| TBI usage, n (%) | <.01∗ | |||||
| TBI (single dose of >500 cGy or fractionated of >800 cGy) | 648 (31) | 79 (38) | 62 (20) | 448 (37) | 59 (16) | |
| TBI (single dose of ≤500 cGy or fractionated ≤ 800 cGy), other agents delivered at MA doses | 59 (3) | 17 (8) | 8 (3) | 33 (3) | 1 (0) | |
| TBI (single dose >200 and ≤500 cGy, or fractionated >200 and ≤800 cGy) | 57 (3) | 12 (6) | 7 (2) | 21 (2) | 17 (5) | |
| TBI of 200 cGy | 267 (13) | 7 (3) | 117 (38) | 126 (10) | 17 (5) | |
| Non-TBI regimen | 1056 (51) | 91 (44) | 109 (36) | 575 (48) | 281 (75) | |
| Missing | 2 (0) | 1 (0) | 1 (0) | 0 (0) | 0 (0) | |
| IV immunoglobulin day 0-100, n (%) | <.01∗ | |||||
| No | 1348 (65) | 87 (42) | 226 (74) | 796 (66) | 239 (64) | |
| Yes | 740 (35) | 120 (58) | 78 (26) | 406 (34) | 136 (36) | |
| Missing | 1 (0) | 0 (0) | 0 (0) | 1 (0) | 0 (0) | |
| Follow-up, median (range), mo | 55 (5-148) | 60 (6-145) | 33 (5-73) | 60 (5-148) | 60 (6-144) |
| Characteristic . | Whole cohort . | TCD . | PTCy . | CNI . | CNI+ATG . | P value . |
|---|---|---|---|---|---|---|
| No. of patients | 2089 | 207 | 304 | 1203 | 375 | |
| No. of centers | 105 | 30 | 46 | 94 | 63 | |
| Patient related | ||||||
| Recipient age, n (%) | <.01∗ | |||||
| Median age (range), y | 51 (2-75) | 52 (3-74) | 56 (2-74) | 47 (2-75) | 53 (2-74) | |
| <.01∗ | ||||||
| <20 years | 459 (22.0) | 43 (20.8) | 23 (7.6) | 307 (25.5) | 86 (22.9) | |
| ≥20 years | 1630 (78.0) | 164 (79.2) | 281 (92.4) | 896 (74.5) | 289 (77.1) | |
| Recipient sex, n (%) | .55∗ | |||||
| Male | 1190 (57) | 126 (61) | 177 (58) | 672 (56) | 215 (57) | |
| Female | 899 (43) | 81 (39) | 127 (42) | 531 (44) | 160 (43) | |
| Recipient race, n (%) | .01∗ | |||||
| White | 1650 (79) | 157 (76) | 221 (73) | 965 (80) | 307 (82) | |
| African American | 235 (11) | 33 (16) | 52 (17) | 109 (9) | 41 (11) | |
| Asian | 100 (5) | 10 (5) | 15 (5) | 60 (5) | 15 (4) | |
| Native Hawaiian or other Pacific Islander | 9 (0) | 1 (0) | 1 (0) | 7 (1) | 0 (0) | |
| American Indian or Alaska Native | 9 (0) | 0 (0) | 0 (0) | 6 (0) | 3 (1) | |
| ≥1 race | 22 (1) | 0 (0) | 4 (1) | 14 (1) | 4 (1) | |
| Missing | 64 (3) | 6 (3) | 11 (4) | 42 (3) | 5 (1) | |
| Ethnicity, n (%) | .02∗ | |||||
| Hispanic or Latino | 223 (11) | 16 (8) | 33 (11) | 146 (12) | 28 (7) | |
| Not Hispanic or Latino | 1816 (87) | 189 (91) | 267 (88) | 1020 (85) | 340 (91) | |
| Nonresident of the United States | 9 (0) | 2 (1) | 1 (0) | 6 (0) | 0 (0) | |
| Missing | 41 (2) | 0 (0) | 3 (1) | 31 (3) | 7 (2) | |
| HCT-CI score, n (%) | <.01∗ | |||||
| 0 | 582 (28) | 50 (24) | 54 (18) | 358 (30) | 120 (32) | |
| 1 | 298 (14) | 27 (13) | 45 (15) | 175 (15) | 51 (14) | |
| 2 | 295 (14) | 30 (14) | 46 (15) | 170 (14) | 49 (13) | |
| ≥3 | 912 (44) | 100 (48) | 159 (52) | 498 (41) | 155 (41) | |
| Missing | 2 (0) | 0 (0) | 0 (0) | 2 (0) | 0 (0) | |
| Previous autologous transplant, n (%) | .17∗ | |||||
| No | 2045 (98) | 199 (96) | 301 (99) | 1178 (98) | 367 (98) | |
| Yes | 44 (2) | 8 (4) | 3 (1) | 25 (2) | 8 (2) | |
| Karnofsky/Lansky performance score, n (%) | .02∗ | |||||
| <90 | 729 (35) | 67 (32) | 125 (41) | 402 (33) | 135 (36) | |
| ≥90 | 1348 (65) | 139 (67) | 175 (58) | 798 (66) | 236 (63) | |
| Missing | 12 (1) | 1 (0) | 4 (1) | 3 (0) | 4 (1) | |
| ALC at HCT, median (range), ×109/L | 2.3 (0.0-77.3) | 2.0 (0.0-77.3) | 2.4 (0.0-23.0) | 2.3 (0.0-74.5) | 2.2 (0.0-42.4) | .50† |
| Missing | 101 (5) | 6 (3) | 7 (2) | 67 (6) | 21 (6) | .05∗ |
| Donor related | ||||||
| Donor age, y | <.01∗ | |||||
| Median (range) | 36 (18-76) | 40 (19-73) | 36 (18-74) | 36 (18-76) | 31 (18-70) | |
| Donor sex, n (%) | .01∗ | |||||
| Male | 1238 (59) | 117 (57) | 199 (65) | 686 (57) | 236 (63) | |
| Female | 805 (39) | 87 (42) | 104 (34) | 483 (40) | 131 (35) | |
| Missing | 46 (2) | 3 (1) | 1 (0) | 34 (3) | 8 (2) | |
| Donor/recipient CMV serostatus, n (%) | <.01∗ | |||||
| +/+ | 511 (24) | 62 (30) | 121 (40) | 236 (20) | 92 (25) | |
| +/− | 173 (8) | 16 (8) | 32 (11) | 83 (7) | 42 (11) | |
| −/+ | 424 (20) | 34 (16) | 82 (27) | 226 (19) | 82 (22) | |
| −/− | 424 (20) | 51 (25) | 67 (22) | 207 (17) | 99 (26) | |
| CB −/recipient + | 333 (16) | 30 (14) | 0 (0) | 267 (22) | 36 (10) | |
| CB −/recipient − | 198 (9) | 11 (5) | 0 (0) | 167 (14) | 20 (5) | |
| CB −/recipient CMV unknown | 7 (0) | 0 (0) | 0 (0) | 7 (1) | 0 (0) | |
| Missing | 19 (1) | 3 (1) | 2 (1) | 10 (1) | 4 (1) | |
| Disease related | ||||||
| Disease, n (%) | <.01∗ | |||||
| AML | 974 (47) | 101 (49) | 157 (52) | 562 (47) | 154 (41) | |
| ALL | 460 (22) | 43 (21) | 64 (21) | 296 (25) | 57 (15) | |
| MDS | 655 (31) | 63 (30) | 83 (27) | 345 (29) | 164 (44) | |
| Time from diagnosis to transplant, median (range), d | 7 (1-549) | 7 (1-370) | 7 (2-549) | 7 (1-364) | 8 (1-497) | .01† |
| AML/ALL disease status, n (%) | .10∗ | |||||
| CR1 | 887 (62) | 92 (64) | 140 (63) | 523 (61) | 132 (63) | |
| CR2 | 348 (24) | 31 (22) | 48 (22) | 219 (26) | 50 (24) | |
| CR≥3 | 56 (4) | 4 (3) | 4 (2) | 40 (5) | 8 (4) | |
| PIF/relapse | 142 (10) | 16 (11) | 29 (13) | 76 (9) | 21 (10) | |
| Missing | 1 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | |
| AML/ALL cytogenetic score, n (%) | .09∗ | |||||
| Normal | 89 (6) | 8 (6) | 9 (4) | 65 (8) | 7 (3) | |
| Favorable | 102 (7) | 9 (6) | 11 (5) | 61 (7) | 21 (10) | |
| Intermediate | 613 (43) | 65 (45) | 100 (45) | 348 (41) | 100 (47) | |
| Poor | 597 (42) | 56 (39) | 99 (45) | 364 (42) | 78 (37) | |
| Not tested | 10 (1) | 3 (2) | 0 (0) | 5 (1) | 2 (1) | |
| Missing | 23 (1) | 3 (2) | 2 (1) | 15 (2) | 3 (1) | |
| MDS IPSS-R cytogenetic score, n (%) | <.01∗ | |||||
| Very good | 6 (1) | 0 (0) | 0 (0) | 4 (1) | 2 (1) | |
| Good | 287 (44) | 23 (37) | 38 (46) | 154 (45) | 72 (44) | |
| Intermediate | 157 (24) | 15 (24) | 18 (22) | 78 (23) | 46 (28) | |
| Poor | 99 (15) | 6 (10) | 9 (11) | 57 (17) | 27 (16) | |
| Very poor | 90 (14) | 12 (19) | 17 (20) | 46 (13) | 15 (9) | |
| Not tested | 8 (1) | 4 (6) | 1 (1) | 2 (1) | 1 (1) | |
| Missing | 8 (1) | 3 (5) | 0 (0) | 4 (1) | 1 (1) | |
| Conditioning intensity, n (%) | <.01∗ | |||||
| MAC | 1370 (66) | 165 (80) | 133 (44) | 846 (70) | 226 (60) | |
| RIC | 480 (23) | 35 (17) | 49 (16) | 271 (23) | 125 (33) | |
| NMA | 237 (11) | 6 (3) | 121 (40) | 86 (7) | 24 (6) | |
| Missing | 2 (0) | 1 (0) | 1 (0) | 0 (0) | 0 (0) | |
| Graft type, n (%) | <.01∗ | |||||
| BM | 336 (16) | 3 (1) | 95 (31) | 178 (15) | 60 (16) | |
| PB | 1215 (58) | 163 (79) | 209 (69) | 584 (49) | 259 (69) | |
| CB | 538 (26) | 41 (20) | 0 (0) | 441 (37) | 56 (15) | |
| Donor group, n (%) | <.01∗ | |||||
| HLA-identical sibling | 412 (20) | 28 (14) | 20 (7) | 322 (27) | 42 (11) | |
| Other related: matched | 27 (1) | 3 (1) | 7 (2) | 17 (1) | 0 (0) | |
| Other related: mismatched 1 antigen/allele | 20 (1) | 2 (1) | 11 (4) | 4 (0) | 3 (1) | |
| Other related: mismatched ≥2 antigen/allele | 269 (13) | 63 (30) | 196 (64) | 9 (1) | 1 (0) | |
| Other related: matching missing | 22 (1) | 3 (1) | 15 (5) | 3 (0) | 1 (0) | |
| Well matched unrelated (8/8) | 670 (32) | 49 (24) | 40 (13) | 369 (31) | 212 (57) | |
| Partially matched unrelated (7/8) | 107 (5) | 15 (7) | 11 (4) | 30 (2) | 51 (14) | |
| Mismatched unrelated (≤6/8) | 11 (1) | 2 (1) | 3 (1) | 1 (0) | 5 (1) | |
| Unrelated (matching unknown) | 13 (1) | 1 (0) | 1 (0) | 7 (1) | 4 (1) | |
| Single cord | 224 (11) | 36 (17) | 0 (0) | 148 (12) | 40 (11) | |
| Double cord | 313 (15) | 5 (2) | 0 (0) | 292 (24) | 16 (4) | |
| CB, single or double unknown | 1 (0) | 0 (0) | 0 (0) | 1 (0) | 0 (0) | |
| GVHD prophylaxis, n (%) | <.01∗ | |||||
| Ex vivo TCD | 62 (3) | 62 (30) | 0 (0) | 0 (0) | 0 (0) | |
| CD34 selection | 145 (7) | 145 (70) | 0 (0) | 0 (0) | 0 (0) | |
| PTCy + other(s) | 286 (14) | 0 (0) | 286 (94) | 0 (0) | 0 (0) | |
| PTCy alone | 18 (1) | 0 (0) | 18 (6) | 0 (0) | 0 (0) | |
| TAC/CSA + MMF ± other(s) (except PTCy) | 662 (32) | 0 (0) | 0 (0) | 537 (45) | 125 (33) | |
| TAC/CSA + MTX ± other(s) (except MMF, PTCy) | 788 (38) | 0 (0) | 0 (0) | 573 (48) | 215 (57) | |
| TAC/CSA + other(s) (except MMF, MTX, and PTCy) | 128 (6) | 0 (0) | 0 (0) | 93 (8) | 35 (9) | |
| ATG/Campath, n (%) | <.01∗ | |||||
| ATG alone | 501 (24) | 126 (61) | 0 (0) | 0 (0) | 375 (100) | |
| No ATG or alemtuzumab | 1588 (76) | 81 (39) | 304 (100) | 1203 (100) | 0 (0) | |
| Steroids, days 0-100, n (%) | <.01∗ | |||||
| No | 1202 (58) | 152 (73) | 200 (66) | 620 (52) | 230 (61) | |
| Yes | 887 (42) | 55 (27) | 104 (34) | 583 (48) | 145 (39) | |
| TBI usage, n (%) | <.01∗ | |||||
| TBI (single dose of >500 cGy or fractionated of >800 cGy) | 648 (31) | 79 (38) | 62 (20) | 448 (37) | 59 (16) | |
| TBI (single dose of ≤500 cGy or fractionated ≤ 800 cGy), other agents delivered at MA doses | 59 (3) | 17 (8) | 8 (3) | 33 (3) | 1 (0) | |
| TBI (single dose >200 and ≤500 cGy, or fractionated >200 and ≤800 cGy) | 57 (3) | 12 (6) | 7 (2) | 21 (2) | 17 (5) | |
| TBI of 200 cGy | 267 (13) | 7 (3) | 117 (38) | 126 (10) | 17 (5) | |
| Non-TBI regimen | 1056 (51) | 91 (44) | 109 (36) | 575 (48) | 281 (75) | |
| Missing | 2 (0) | 1 (0) | 1 (0) | 0 (0) | 0 (0) | |
| IV immunoglobulin day 0-100, n (%) | <.01∗ | |||||
| No | 1348 (65) | 87 (42) | 226 (74) | 796 (66) | 239 (64) | |
| Yes | 740 (35) | 120 (58) | 78 (26) | 406 (34) | 136 (36) | |
| Missing | 1 (0) | 0 (0) | 0 (0) | 1 (0) | 0 (0) | |
| Follow-up, median (range), mo | 55 (5-148) | 60 (6-145) | 33 (5-73) | 60 (5-148) | 60 (6-144) |
ALC, absolute lymphocyte count; CB, cord blood; CMV, cytomegalovirus; CR1/2/3, complete remission; CSA, cyclosporin; HCT-CI, HCT-specific comorbidity index; IPSS-R, revised international prognostic scoring system; MA, myeloablative; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MTX, methotrexate; NMA, non-myeloablative; PIF, primary induction failure; RIC, reduced intensity conditioning; TAC, tacrolimus.
Pearson χ2 test.
Kruskal-Wallis test.